NCT02965716: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma